|
1
|
Boussen H, Bouzaiene H, Ben Hassouna J, et
al: Inflammatory breast cancer in Tunisia: epidemiological and
clinical trends. Cancer. 116:2730–2735. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maalej M, Hentati D, Messai T, et al:
Breast cancer in Tunisia in 2004: a comparative clinical and
epidemiological study. Bull Cancer. 95:E5–E9. 2008.PubMed/NCBI
|
|
3
|
Missaoui N, Jaidene L, Abdelkrim SB, et
al: Breast cancer in Tunisia: clinical and pathological findings.
Asian Pac J Cancer Prev. 12:169–172. 2011.PubMed/NCBI
|
|
4
|
Lichtenstein P, Holm NV and Verkasalo PK:
Environmental and heritable factors in the causation of cancer. N
Engl J Med. 343:78–85. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nebert DW and Dalton TP: The role of
cytochrome P450 enzymes in endogenous signalling pathways and
environmental carcinogenesis. Nat Rev Cancer. 6:947–960. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nebert DW, Yamazaki H, Shaw PM, Guengerich
FP and Shimada T: Roles of cytochromes P450 1A2 and 3A4 in the
oxidation of estradiol and estrone in human liver microsomes. Chem
Res Toxicol. 11:659–665. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsuchiya Y, Nakajima M and Yokoi T:
Cytochrome P450-mediated metabolism of estrogens and its regulation
in human. Cancer Lett. 227:115–124. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou SF, Wang B, Yang LP and Liu JP:
Structure, function, regulation and polymorphism and the clinical
significance of human cytochrome P450 1A2. Drug Metab Rev.
42:268–354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wen ZH, Su YC, Lai PL, et al: Critical
role of arachidonic acid-activated mTOR signaling in breast
carcinogenesis and angiogenesis. Oncogene. Feb 20–2012.(Epub ahead
of print). View Article : Google Scholar
|
|
10
|
Djordjevic N, Ghotbi R, Bertilsson L,
Jankovic S and Aklillu E: Induction of CYP1A2 by heavy coffee
consumption in Serbs and Swedes. Eur J Clin Pharmacol. 64:381–385.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Granfors MT, Backman JT, Laitila J and
Neuvonen PJ: Oral contraceptives containing ethinyl estradiol and
gestodene markedly increase plasma concentrations and effects of
tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther.
78:400–411. 2005. View Article : Google Scholar
|
|
12
|
Kall MA, Vang O and Clausen J: Effects of
dietary broccoli on human in vivo drug metabolising enzymes:
evaluation of caffeine, estrone and chlozoxazone metabolism.
Carcinogenesis. 17:793–799. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lampe JW, King IB, Li S, et al: Brassica
vegetables increase and apiaceous vegetables decrease cytochrome
P450 1A2 activity in humans: changes in caffeine metabolite ratios
in response to controlled vegetable diets. Carcinogenesis.
21:1157–1162. 2000. View Article : Google Scholar
|
|
14
|
Schrenk D, Brockmeier D, Mörike K, Bock KW
and Eichelbaum MA: Distribution study of CYP1A2 phenotypes among
smokers and non-smokers in a cohort of healthy Caucasian
volunteers. Eur J Clin Pharmacol. 53:361–367. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sinha R, Rothman N, Brown ED, et al:
Pan-fried meat containing high levels of heterocyclic aromatic
amines but low levels of polycyclic aromatic hydrocarbons induces
cytochrome P4501A2 activity in humans. Cancer Res. 54:6154–6159.
1994.
|
|
16
|
Dobrinas M, Cornuz J, Oneda B, Kohler
Serra M, Puhl M and Eap CB: Impact of smoking, smoking cessation,
and genetic polymorphisms on CYP1A2 activity and inducibility. Clin
Pharmacol Ther. 90:117–125. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gunes A, Ozbey G, Vural EH, et al:
Influence of genetic polymorphisms, smoking, gender and age on
CYP1A2 activity in a Turkish population. Pharmacogenomics.
10:769–778. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ghotbi R, Christensen M, Roh HK,
Ingelman-Sundberg M, Aklillu E and Bertilsson L: Comparisons of
CYP1A2 genetic polymorphisms, enzyme activity and the
genotype-phenotype relationship in Swedes and Koreans. Eur J Clin
Pharmacol. 63:537–546. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakajima M, Yokoi T, Mizutani M, Kinoshita
M, Funayama M and Kamataki T: Genetic polymorphism in the
5′-flanking region of human CYP1A2 gene: effect on the CYP1A2
inducibility in humans. J Biochem. 125:803–808. 1999.
|
|
20
|
Pavanello S, Pulliero A, Lupi S, Gregorio
P and Clonfero E: Influence of the genetic polymorphism in the
5′-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and
urinary mutagenicity in smokers. Mutat Res. 587:59–66. 2005.
|
|
21
|
Sachse C, Brockmöller J, Bauer S and Roots
I: Functional significance of a C-->A polymorphism in intron 1
of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin
Pharmacol. 47:445–449. 1999.
|
|
22
|
Pavanello S, B'chir F, Pulliero A, et al:
Interaction between CYP1A2-T2467delT polymorphism and smoking in
adenocarcinoma and squamous cell carcinoma of the lung. Lung
Cancer. 57:266–272. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pavanello S, Mastrangelo G, Placidi D, et
al: CYP1A2 polymorphisms, occupational and environmental exposures
and risk of bladder cancer. Eur J Epidemiol. 25:491–500. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bonner MR, Bennet WP, Xiong W, et al:
Radon, secondhand smoke, glutathione-S-transferase M1 and lung
cancer among women. Int J Cancer. 119:1462–1467. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qiu LX, Yao L, Mao C, et al: Lack of
association of CYP1A2-164 A/C polymorphism with breast cancer
susceptibility: a meta-analysis involving 17,600 subjects. Breast
Cancer Res Treat. 122:521–525. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mechanic LE, Marrogi AJ, Welsh JA, et al:
Polymorphisms in XPD and TP53 and mutation in human lung cancer.
Carcinogenesis. 26:597–604. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pavanello S, Fedeli U, Mastrangelo G, et
al: Role of CYP1A2 polymorphisms on lung cancer risk in a
prospective study. Cancer genetics. 205:278–284. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Le Marchand L, Donlon T, Kolonel LN,
Henderson BE and Wilkens LR: Estrogen metabolism-related genes and
breast cancer risk: the multiethnic cohort study. Cancer Epidemiol
Biomark Prev. 14:1998–2003. 2005.PubMed/NCBI
|
|
29
|
Long JR, Egan KM, Dunning L, et al:
Population-based case-control study of AhR (aryl hydrocarbon
receptor) and CYP1A2 polymorphisms and breast cancer risk.
Pharmacogenet Genomics. 16:237–243. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kotsopoulos J, Ghadirian P, El-Sohemy A,
et al: The CYP1A2 genotype modifies the association between coffee
consumption and breast cancer risk among BRCA1 mutation carriers.
Cancer Epidemiol Biomark Prev. 16:912–916. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takata Y, Maskarinec G and Le Marchand L:
Breast density and polymorphisms in genes coding for CYP1A2 and
COMT: the multiethnic cohort. BMC Cancer. 7:302007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bågeman E, Ingvar C, Rose C and Jernström
H: Coffee consumption and CYP1A2*1F genotype modify age at breast
cancer diagnosis and estrogen receptor status. Cancer Epidemiol
Biomark Prev. 17:895–901. 2008.
|
|
33
|
Sangrajrang S, Sato Y, Sakamoto H, et al:
Genetic polymorphisms of estrogen metabolizing enzyme and breast
cancer risk in Thai women. Int J Cancer. 125:837–843. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shimada N, Iwasaki M, Kasuga Y, et al:
Genetic polymorphisms in estrogen metabolism and breast cancer risk
in case-control studies in Japanese, Japanese Brazilians and
non-Japanese Brazilians. J Hum Genet. 54:209–215. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chang-Claude J, Beckmann L, Corson C, et
al: MARIE-GENICA consortium on genetic susceptibility for
menopausal hormone therapy related breast cancer Risk. Genetic
polymorphisms in phase I and phase II enzymes and breast cancer
risk associated with menopausal hormone therapy in postmenopausal
women. Breast Cancer Res Treat. 119:463–474. 2010. View Article : Google Scholar
|
|
36
|
Gulyaeva LF, Mikhailova ON, PustyInyak VO,
et al: Comparative analysis of SNP in estrogen-metabolizing enzymes
for ovarian, endometrial, and BCs in Novosibirsk, Russia. Adv Exp
Med Biol. 617:359–366. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Quattrochi LC, Vu T and Tukey RH: The
human CYP1A2 gene and induction by 3-methylcholanthrene. A region
of DNA that supports AH-receptor binding and promoter-specific
induction. J Biol Chem. 269:6949–6954. 1994.PubMed/NCBI
|
|
38
|
Sogawa K and Fujii-Kuriyama Y: Ah
receptor, a novel ligand-activated transcription factor. J Biochem.
122:1075–1079. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hankinson O: The aryl hydrocarbon receptor
complex. Annual Rev Pharmacol Toxicol. 35:307–340. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pavanello S, Pulliero A, Saia BO and
Clonfero E: Determinants of anti-benzo(a)pyrene diol epoxide-DNA
adduct formation in lymphomonocytes of the general population.
Mutat Res. 611:54–63. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Martucci CP and Fishman J: P450 enzymes of
estrogen metabolism. Pharmacol Ther. 57:237–257. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Meilahn EN, De Stavola B, Allen DS, et al:
Do urinary oestrogen metabolites predict breast cancer? Guernsey
III cohort follow-up. Br J Cancer. 78:1250–1255. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Muti P, Bradlow HL, Micheli A, et al:
Estrogen metabolism and risk of breast cancer: a prospective study
of the 2:16α-hydroxyestrone ratio in premenopausal and
postmenopausal women. Epidemiology. 11:635–640. 2000.
|
|
44
|
Kabat GC, Chang CJ, Sparano JA, et al:
Urinary estrogen metabolites and breast cancer: a case-control
study. Cancer Epidemiol Biomarkers Prev. 6:505–509. 1997.PubMed/NCBI
|
|
45
|
Liehr JG and Ricci MJ: 4-Hydroxylation of
estrogens as marker of human mammary tumors. Proc Natl Acad Sci
USA. 93:3294–3296. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Telang NT, Suto A, Wong GY, Osborne MP and
Bradlow HL: Induction by estrogen metabolite 16-hydroxyestrone of
genotoxic damage and aberrant proliferation in mouse mammary
epithelial cells. J Natl Cancer Inst. 84:634–638. 1992. View Article : Google Scholar : PubMed/NCBI
|
